PURPOSE: Given their accessibility, surrogate tissues, such as peripheral blood mononuclear cells (PBMC), may provide potential predictive biomarkers in clinical pharmacogenomic studies. In leukemias and lymphomas, the prognostic value of peripheral blast expression profiles is clear; however, it is unclear whether circulating mononuclear cells of patients with solid tumors might yield profiles with similar prognostic associations. EXPERIMENTAL DESIGN: In this study, we evaluated the association of expression profiles in PBMCs with clinical outcomes in patients with advanced renal cell cancer. Transcriptional patterns in PBMCs of 45 renal cell cancer patients were compared with clinical outcome data at the conclusion of a phase II study of the mTOR kinase inhibitor CCI-779 to determine whether pretreatment transcriptional patterns in PBMCs were correlated with eventual patient outcomes. RESULTS: Unsupervised hierarchical clustering of the PBMC profiles using all expressed genes identified clusters of patients with significant differences in survival. Cox proportional hazards modeling showed that the expression levels of many PBMC transcripts were predictors for the patient outcomes of time to progression and overall survival (time to death). Supervised class prediction approaches identified multivariate expression patterns in PBMCs capable of assigning favorable outcomes of time to death and time to progression in a test set of renal cancer patients, with overall performance accuracies of 72% and 85%, respectively. CONCLUSIONS: The present study provides the first example of gene expression profiling in peripheral blood, a clinically accessible surrogate tissue, for identifying patterns of gene expression associated with higher likelihoods of positive outcome in patients with a solid tumor.
PURPOSE: Given their accessibility, surrogate tissues, such as peripheral blood mononuclear cells (PBMC), may provide potential predictive biomarkers in clinical pharmacogenomic studies. In leukemias and lymphomas, the prognostic value of peripheral blast expression profiles is clear; however, it is unclear whether circulating mononuclear cells of patients with solid tumors might yield profiles with similar prognostic associations. EXPERIMENTAL DESIGN: In this study, we evaluated the association of expression profiles in PBMCs with clinical outcomes in patients with advanced renal cell cancer. Transcriptional patterns in PBMCs of 45 renal cell cancerpatients were compared with clinical outcome data at the conclusion of a phase II study of the mTOR kinase inhibitor CCI-779 to determine whether pretreatment transcriptional patterns in PBMCs were correlated with eventual patient outcomes. RESULTS: Unsupervised hierarchical clustering of the PBMC profiles using all expressed genes identified clusters of patients with significant differences in survival. Cox proportional hazards modeling showed that the expression levels of many PBMC transcripts were predictors for the patient outcomes of time to progression and overall survival (time to death). Supervised class prediction approaches identified multivariate expression patterns in PBMCs capable of assigning favorable outcomes of time to death and time to progression in a test set of renal cancerpatients, with overall performance accuracies of 72% and 85%, respectively. CONCLUSIONS: The present study provides the first example of gene expression profiling in peripheral blood, a clinically accessible surrogate tissue, for identifying patterns of gene expression associated with higher likelihoods of positive outcome in patients with a solid tumor.
Authors: Federico M Goodsaid; Shashi Amur; Jiri Aubrecht; Michael E Burczynski; Kevin Carl; Jennifer Catalano; Rosane Charlab; Sandra Close; Catherine Cornu-Artis; Laurent Essioux; Albert J Fornace; Lois Hinman; Huixiao Hong; Ian Hunt; David Jacobson-Kram; Ansar Jawaid; David Laurie; Lawrence Lesko; Heng-Hong Li; Klaus Lindpaintner; James Mayne; Peter Morrow; Marisa Papaluca-Amati; Timothy W Robison; John Roth; Ina Schuppe-Koistinen; Leming Shi; Olivia Spleiss; Weida Tong; Sharada L Truter; Jacky Vonderscher; Agnes Westelinck; Li Zhang; Issam Zineh Journal: Nat Rev Drug Discov Date: 2010-06 Impact factor: 84.694
Authors: Thomas Hofmann; Stefanie Klenow; Anke Borowicki; Chris I R Gill; Beatrice L Pool-Zobel; Michael Glei Journal: Genes Nutr Date: 2010-02-09 Impact factor: 5.523
Authors: Murty V Chengalvala; Vargheese M Chennathukuzhi; Daniel S Johnston; Panayiotis E Stevis; Gregory S Kopf Journal: Curr Genomics Date: 2007-06 Impact factor: 2.236
Authors: Kim A Eagle; Geoffrey S Ginsburg; Kiran Musunuru; William C Aird; Robert S Balaban; Susan K Bennett; Roger S Blumenthal; Shaun R Coughlin; Karina W Davidson; Edward D Frohlich; Philip Greenland; Gail P Jarvik; Peter Libby; Carl J Pepine; Jeremy N Ruskin; Arthur E Stillman; Jennifer E Van Eyk; H Eser Tolunay; Cheryl L McDonald; Sidney C Smith Journal: Circulation Date: 2010-03-30 Impact factor: 29.690
Authors: Carolina Arenas Valencia; Liliana Lopez Kleine; Andres M Pinzon Velasco; Andrea Y Cardona Barreto; Clara E Arteaga Diaz Journal: Fam Cancer Date: 2018-10 Impact factor: 2.375
Authors: Christopher H Woelk; Nadejda Beliakova-Bethell; Miguel Goicoechea; Yingdong Zhao; Pinyi Du; Steffney E Rought; Jean Lozach; Josué Pérez-Santiago; Douglas D Richman; Davey M Smith; Susan J Little Journal: AIDS Date: 2010-01-16 Impact factor: 4.177
Authors: Michael K Showe; Anil Vachani; Andrew V Kossenkov; Malik Yousef; Calen Nichols; Elena V Nikonova; Celia Chang; John Kucharczuk; Bao Tran; Elliot Wakeam; Ting An Yie; David Speicher; William N Rom; Steven Albelda; Louise C Showe Journal: Cancer Res Date: 2009-12-15 Impact factor: 12.701